Theriva Biologics, Inc. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
Theriva Biologics, Inc. (TOVX) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $6.60 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2022-08-11
- Theriva Biologics, Inc. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2022-03-31 was $6.60M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 3 month |
|---|---|---|
| 2022-03-31 | $6.60M 10-Q · filed 2022-05-16 | |
| 2022-03-10 | $6.60M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |